Natera director Chapman Rowan E sells shares worth over $333k

In a recent transaction, Natera, Inc. (NASDAQ:NTRA ) Director Chapman Rowan E sold 2,614 shares of the company's common stock, according to a Form 4 filing with the Securities and Exchange Commission. The sale, dated September 13, 2024, was executed at an average price of $127.68 per share, resulting in a total value of approximately $333,755.


On the same day, the director also acquired 2,614 shares through the exercise of options, with the transaction valued at $94.14 per share, which totals around $246,081. Notably, this transaction did not result in any net increase in Chapman's overall holdings, as the shares acquired were immediately sold.


Following these transactions, Chapman Rowan E's direct ownership in Natera stands at 7,969 shares. The company, which specializes in medical laboratories and is incorporated in Delaware, has its business address in Austin, Texas.


Investors often monitor insider transactions as they may provide insights into the company's financial health and future prospects. The sale and acquisition of shares by company insiders, such as directors, can be routine and part of their compensation structure, but they are required to be disclosed to the public through SEC filings. These transactions are of interest to investors who look to them for signals about management's confidence in the company's performance and outlook.


Natera, Inc. continues to operate in the healthcare sector, providing a range of services including genetic testing. Insider transactions such as these are closely watched by the market for indications of the company's valuation and the insiders' perspective on the stock's potential.



In other recent news, Natera Inc . has been the subject of several analyst reports. Piper Sandler reiterated a $150 price target on Natera shares, emphasizing the significance of the upcoming Galaxy study results. TD Cowen also maintained a Buy rating, expressing optimism about Natera's potential findings to be presented at the European Society for Medical Oncology (ESMO) 2024 conference. Canaccord Genuity, likewise, kept a Buy rating on Natera with a price target of $145, highlighting the company's presentation of new data from the CIRCULATE-Japan trial at the ESMO Congress.


Natera's Q2 results showed a 12% sequential revenue increase from Q1 and a 58% surge year-over-year, leading the company to raise its full-year revenue guidance to approximately $1.5 billion. The gross margin expectation stands at 55%, accompanied by a record number of test volumes and a rise in average selling prices. These are recent developments that underline the company's strong growth and robust financial performance.


Furthermore, Natera's Renasight test received an endorsement from the National Kidney Foundation for chronic kidney disease testing. Despite a delay in the submission of the ALTAIR study and the non-renewal of the Foundation Medicine partnership, the company anticipates steady sequential growth in volumes and revenue, projecting a 40% revenue growth compared to 2023.
InvestingPro Insights


Amidst the insider transactions at Natera, Inc. (NASDAQ:NTRA), investors are weighing the company's financial metrics and market performance to gauge its outlook. According to real-time data from InvestingPro, Natera's market capitalization stands at a robust $16.1 billion. This reflects the company's significant presence in the medical laboratories industry. With a Price to Book (P/B) ratio of 19.17 as of the last twelve months leading up to Q2 2024, the stock is trading at a premium compared to book value, which could be indicative of the market's high expectations for the company's future growth.


InvestingPro Tips suggest that the stock's price movements have been quite volatile, which may influence investor sentiment. Additionally, while analysts have recently revised their earnings estimates upwards for the upcoming period, they do not anticipate Natera to be profitable this year. This could be a point of consideration for those looking at the long-term potential of the company. Notably, Natera has been trading near its 52-week high, with a price that is 98.23% of this peak, signifying strong investor interest and confidence in recent times.


For those interested in further insights, InvestingPro offers additional tips on Natera, Inc., which could be valuable for a deeper analysis of the company's performance and prospects. As of now, there are 11 more tips listed on InvestingPro, which can be accessed for more detailed guidance and investment considerations.


Understanding the financial health and market sentiment around Natera is crucial, especially in light of insider transactions. The company's revenue growth of 46.13% over the last twelve months as of Q2 2024, alongside a significant price uptick over the last six months of 41.32%, paints a picture of a company that is expanding rapidly, despite the lack of profitability in the near term. These metrics and insights from InvestingPro could help investors make more informed decisions in the dynamic healthcare sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com